Profund Advisors’s Akero Therapeutics AKRO Stock Holding History

Profund Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-29,093	Closed	-$1.38M	–	1251
2025 Q3	$1.38M	Buy	29,093 +9,288	+47%	+$450K	0.04%	260
2025 Q2	$1.06M	Buy	19,805 +3,757	+23%	+$171K	0.04%	288
2025 Q1	$650K	Buy	16,048 +1,196	+8%	+$50.7K	0.03%	404
2024 Q4	$413K	Sell	14,852 -3,667	-20%	-$111K	0.02%	608
2024 Q3	$531K	Sell	18,519 -4,319	-19%	-$113K	0.02%	510
2024 Q2	$536K	Sell	22,838 -23,032	-50%	-$493K	0.02%	480
2024 Q1	$1.16M	Sell	45,870 -26,674	-37%	-$641K	0.05%	324
2023 Q4	$1.69M	Buy	72,544 +41,322	+132%	+$815K	0.07%	205
2023 Q3	$1.58M	Buy	31,222 +2,228	+8%	+$104K	0.09%	180
2023 Q2	$1.35M	Sell	28,994 -1,584	-5%	-$72.6K	0.07%	240
2023 Q1	$1.17M	Buy	+30,578	New	+$1.36M	0.07%	265

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Profund Advisors's AKRO Position: Q4 2025 in Review

Profund Advisors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 29,093 shares — an estimated $1.38M sold.

Profund Advisors first reported a position in AKRO in Q1 2023 and held it in 11 quarters. The position peaked at $1.69M in Q4 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Profund Advisors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Profund Advisors sold 29,093 Akero Therapeutics shares in Q4 2025, an estimated $1.38M.
Profund Advisors first reported a position in Akero Therapeutics in Q1 2023 and held it in 11 quarters.
Profund Advisors's Akero Therapeutics position peaked at $1.69M in Q4 2023.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Profund Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.